Cure8 research brief
A stable small gene panel that flags active mucosal inflammation could help research into objective biomarkers for UC and eventually support diagnosis or monitoring if prospectively validated. The finding that it does not detect non-inflamed UC mucosa or predict infliximab response limits immediate clinical utility.
Researchers working on biomarkers or transcriptomics in IBD; clinicians interested in biomarker-driven assessment of mucosal inflammation; patients and clinicians involved in trials of biologics (infliximab) where predictive biomarkers are sought.
This study used repeated, nested cross-validation on public colonic mucosal transcriptomic datasets to select seven genes (CASP1, SAA1, LCN2, DUOX2, LPCAT3, IDO1, DEFA6) that together discriminate inflamed UC mucosa from healthy controls with high AUCs in external cohorts.
The panel performed well for active/inflamed tissue contrasts (AUCs often >0.9) but did not separate macroscopically non-inflamed UC mucosa from healthy mucosa (near-chance AUC ~0.53). The panel also did not predict baseline response to infliximab in the evaluated dataset.
Next steps and limitations: The authors note the score mainly reflects active mucosal inflammation and requires prospective validation with a fixed reference before clinical use. This report is grounded in the source-provided abstract and represents a model-development and multicohort evaluation rather than a prospective clinical validation.
Structured content depth: abstract — the classification and curator note are based on the article abstract and reported multicohort evaluation. The panel was derived from public transcriptomic datasets and requires prospective fixed-reference evaluation before clinical application. The infliximab-response discrimination was poor in the dataset analyzed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
If local norepinephrine promotes neutrophil‑driven inflammation in UC, that could help explain disease progression in some patients and point to biomarkers (ADRB2‑rich neutrophils) that might predict response to anti‑TNF...
If validated, mucosal biomarkers like SPARC and SPP1 might help predict who will not respond to infliximab, potentially guiding treatment choices and avoiding ineffective therapy for some people with UC.
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
